Rifapentine and Liver disease
Result of checking the interaction of drug Rifapentine and disease Liver disease for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Although the single-dose pharmacokinetic profiles of rifapentine and its active metabolite, 25-desacetyl rifapentine, are not significantly altered in patients with hepatic impairment compared to healthy individuals, therapy with rifapentine should be administered cautiously in such patients, since the drug is primarily eliminated by the liver. Dosage adjustments may be necessary if undue adverse effects occur. In addition, many antituberculous agents, including the rifamycins, are associated with hepatotoxicity. Patients with abnormal liver function tests and/or liver disease should only be given rifapentine after careful consideration of risks and benefits. If a decision is made to use the drug, liver function tests, especially serum transaminases, should be obtained every 2 to 4 weeks during therapy. Rifapentine should be discontinued if liver disease worsens.
- "Product Information. Priftin (rifapentine)." Hoechst Marion-Roussel Inc, Kansas City, MO.